CAS 1372540-25-4
:GSK2636771
Description:
GSK2636771 is a chemical compound developed by GlaxoSmithKline, primarily investigated for its potential therapeutic applications in the treatment of various diseases, including certain types of cancer. It is classified as a small molecule inhibitor, specifically targeting certain kinases involved in cellular signaling pathways. The compound's structure includes specific functional groups that contribute to its biological activity and selectivity. GSK2636771 has been studied for its ability to modulate key pathways that regulate cell proliferation and survival, making it a candidate for targeted therapy. In preclinical studies, it has shown promise in inhibiting tumor growth and enhancing the efficacy of other treatments. As with many investigational drugs, its safety, efficacy, and pharmacokinetic properties are evaluated through rigorous clinical trials. The compound's development reflects ongoing efforts in the pharmaceutical industry to create more effective and targeted cancer therapies, although detailed information on its clinical status and specific mechanisms of action may vary as research progresses.
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 5 products.
2-Methyl-1-(2-Methyl-3-(Trifluoromethyl)Benzyl)-6-Morpholino-1H-Benzo[D]Imidazole-4-Carboxylic Acid
CAS:<p>2-Methyl-1-(2-Methyl-3-(Trifluoromethyl)Benzyl)-6-Morpholino-1H-Benzo[D]Imidazole-4-Carboxylic Acid</p>Purity:98%Molecular weight:433.42g/molGSK2636771
CAS:<p>GSK2636771, an effective, specific, orally bioavailable, PI3Kβ inhibitor, has been used in cancer, lymphoma, solid neoplasm, recurrent solid neoplasm, and</p>Formula:C22H22F3N3O3Purity:98.58% - ≥95%Color and Shape:SolidMolecular weight:433.42
![2-Methyl-1-(2-Methyl-3-(Trifluoromethyl)Benzyl)-6-Morpholino-1H-Benzo[D]Imidazole-4-Carboxylic Acid](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2F54%2Fthumb%2FPC108720.jpg&w=3840&q=75)
